Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 May 8:2025.05.08.25327221.
doi: 10.1101/2025.05.08.25327221.

Intensity of public health and social measures are associated with effectiveness of SARS-CoV-2 vaccine in test-negative study

Affiliations

Intensity of public health and social measures are associated with effectiveness of SARS-CoV-2 vaccine in test-negative study

Tim K Tsang et al. medRxiv. .

Abstract

The intensity and duration of exposure can influence vaccine effectiveness (VE). For "leaky" vaccines such as SARS-CoV-2 vaccines, which reduce but do not entirely prevent infections, repeated or prolonged exposures may increase breakthrough infection likelihood. To test this hypothesis, we conducted a systematic review and meta-analysis of 76 test-negative design studies reporting VE against SARS-CoV-2 infection or severe disease. Exposure intensity was approximated using Oxford COVID-19 Government Response Tracker indices: Stringency Index (SI), Containment and Health Index (CHI), and Government Response Index (GRI). Based on 1,419 VE estimates, pooled VE against infection was significantly higher in settings with higher index values (lower exposure intensity): 82% (95% CI: 80-83%) in high-SI settings versus 39% (95% CI: 35-43%) in low-SI settings. Similar patterns appeared for other indices and severe disease outcomes. These associations persisted in meta-regression models adjusting for viral variant, vaccine type, time since vaccination, prior infection status, and enrollment criteria. Correlation analyses showed moderate-to-strong positive correlations between VE estimates and exposure indices (Spearman's correlation: 0.50-0.62). These findings establish exposure intensity as a critical effect modifier of SARS-CoV-2 VE, demonstrating the leaky nature of COVID-19 vaccines and explaining heterogeneity in real-world effectiveness estimates. Future VE evaluations and vaccination strategies should account for exposure intensity to ensure accurate, context-specific estimates.

Keywords: COVID-19; SARS-CoV-2; pre-existing immunity; test-negative design; vaccination; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Competing Interests BJC reports honoraria from AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Pfizer, Roche and Sanofi Pasteur. SGS reports consulting for AstraZeneca, CSL Seqirus, GSK, Moderna, Novavax, Pfizer, and Sanofi. The authors report no other potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Selection of studies for the systematic review
Figure 2.
Figure 2.
Association between vaccine effectiveness (VE) and public health indices. Scatterplots illustrating the relationship between VE and the Stringency Index (SI), Containment and Health Index (CHI), and Government Response Index (GRI) for different outcomes (infection and severe disease). Correlation coefficients (r and ρ) are shown for the overall dataset and stratified by variant periods (pre-Delta and Delta, late-Delta, Omicron BA.1/BA.2, Omicron BA.4/BA.5). The figures demonstrate positive correlations between VE and higher index values, indicating that stricter public health measures are associated with increased VE.
Figure 3.
Figure 3.
Impact of public health indices on pooled vaccine effectiveness (VE). Meta-analysis results comparing VE across tertiles of the Stringency Index (SI), Containment and Health Index (CHI), and Government Response Index (GRI). The pooled VE is significantly higher in the highest tertile of each index, suggesting that stricter control measures, and consequently lower exposure levels, are associated with improved VE against both infection and severe disease.

Similar articles

References

    1. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51. - PubMed
    1. Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. Bmj. 2021;375:e068848. - PMC - PubMed
    1. Andrews1 N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022. - PMC - PubMed
    1. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022. - PMC - PubMed
    1. Chemaitelly2 H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614–21. - PubMed

Publication types

LinkOut - more resources